CO2 as a Stress Agent for Perfusion Imaging

Not Applicable

Terminated

• Conditions: Coronary Artery Disease

• Registration Number: NCT02043535
• Lead Sponsor: Ottawa Heart Institute Research Corporation

Brief Summary

Myocardial perfusion imaging (MPI) is a nuclear scan using a radioisotope to see blood flow to the muscles of the heart when the heart is at rest and when it is under stress. The stress test in MPI can be done using medications, such as persantine, that dilate coronary arteries and increase blood flow. Similarly, elevated carbon dioxide (CO2) levels in the blood, or hypercapnia, also dilates arteries and increases blood flow. Thornhill Research Inc. has developed the RA-MR™ sequential gas delivery system used to control CO2 levels in the blood. The RA-MR™ can deliver precise amounts of CO2 through a mouthpiece for inhalation to increase CO2 levels in the blood and thereby increasing blood flow like during stress.

The objective of this study is to compare the differences in blood flow through the arteries of the heart during stress with hypercapnia and adenosine MPI. The imaging will be done using positron emission tomography (PET) with the radioisotope, or tracer, called Rubidium (Rb-82). The Rb-82 is given through a pump, or elution system.

The investigators hypothesize that hypercapnia will induce a stress-to-rest increase in myocardial blood flow by a factor of 2 or more in myocardial regions supplied by non-stenotic arteries in normal volunteers and participants with coronary artery disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-01-03
• Study First Submitted QC: 2014-01-21
• Study First Posted: 2014-01-23
• Study Start: 2014-03-12
• Primary Completion: 2020-10-15
• Study Completion: 2020-10-15
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-30
• Last Update Posted: 2021-04-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

For all participants

• Age ≥ 18 years old
• BMI ≤ 40 kg/m2
• Able and willing to comply with the study procedures
• Written informed consent
• Participants with documented coronary artery disease
• Stable coronary artery disease on a stable medication regime.
• Healthy volunteers without known heart disease
• Low risk of coronary artery disease (CAD)

Exclusion Criteria

• History or risk of severe bradycardia (heart rate < 50 beats per minute) not related to chronotropic drugs
• Known second- or third-degree Atrio-ventricular block without pacemaker
• Atrial flutter or atrial fibrillation
• Dyspnea (NYHA III/IV), wheezing asthma or Chronic Obstructive Pulmonary Disease (COPD)
• Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or at any time after consent
• Percutaneous coronary intervention (PCI) within 30 days prior to screening or at any time following consent
• Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent
• Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
• Known hypersensitivity to adenosine
• Breastfeeding or pregnancy
• Claustrophobia or inability to lie still in a supine position
• Unwillingness or inability to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Myocardial blood flow differences	Difference between baseline rest scan blood flow and hypercapnia stress scan myocardial blood flow at 50 mmHg, 55 mmHg, 60 mmHg levels from baseline. Imaging and intervention analysis will be complete in 4 years.	The myocardial blood flow (MBF) will be quantified with each Rb-82 PET scan done. Polar-maps representing MBF are generated for each rest and stress state using in-house FlowQuant©software. The rest scan will be the baseline. The myocardial blood flow in the four stress scans using hypercapnia as a stress agent will be compared to the rest baseline myocardial blood flow and the adenosine stress scan myocardial blood flow.

Secondary Outcome Measures

Name	Time	Method
Difference bewteen absolute myocardial blood flow with hypercapnia and with adenosine stress.	Quantification and comparison of the differences in myocardial blood flow with adenosine stress and increasing levels of CO2 as a stress agent. Imaging and intervention analysis will be complete in 4 years.	The effects of hypercapnia and adenosine on absolute myocardial blood flow using Rb-82 PET will be compared. Polar-maps representing MBF are generated for each stress state using in-house FlowQuant©software.
Absolute myocardial blood flow differences between end-tidal CO2 scans	Difference between baseline and 60 mmHg PetCO2. Imaging and intervention analysis will be complete in 4 years.	The effect of increasing doses of pulmonary end-tidal carbon dioxide tension (PetCO2) will be measured and quantification of absolute myocardial blood flow using Rb-82 PET will be calculated. Polar-maps representing MBF are generated for each stress state using in-house FlowQuant©software. Five levels will be measured.

Trial Locations

Locations (1)

University Of Ottawa Heart Institute; 🇨🇦 Ottawa, Ontario, Canada